Medicare proposes covering expensive Alzheimer’s drug for those in clinical trials

The Biogen Inc., headquarters is shown in Cambridge, Mass. Medicare says it will limit coverage of a $28,200-per-year Alzheimer

Aduhelm is the first treatment approved in the country to slow cognitive decline in those living with Alzheimer’s. Doctors have refused to prescribe it, given the lack of data and evidence behind it.

(Image credit: Steven Senne/AP)

Read the full post on Health Care : NPR